OptiScan Biomedical has launched its OptiScanner 6000, a next-generation continuous monitoring platform for intensive care units.
OptiScanner 6000 is an automated, plasma-based bedside glucose monitoring system that automatically measures and trends multiple analytes including glucose, ScvO2 (oxygen in the superior vena cava of the heart), and haemoglobin.
The next-generation device requires no calibration and provides clinicians with real-time and trending data supporting early detection of changes in the critically ill.
OptiScan Biomedical introduced the new OptiScanner 6000 as part of a special symposium at the 34th International Symposium on Intensive Care and Emergency Medicine being held this week in Brussels, Belgium.
OptiScanner draws 0.12mL of patient blood every 15 minutes, which it converts to plasma in a micro-centrifuge and then transports the plasma to be read by mid-range infrared spectrometer.
A proprietary algorithm automatically adjusts for interferences and within a few minutes of the blood draw, a glucose reading is displayed on the front of the OptiScanner.
As the OptiScanner provides a glucose reading every 15 minutes, glycaemic trends can be displayed prominently, indicating whether patient's glucose is stable (euglycemia), rising too high (hyperglycemia) or falling too low (hypoglycemia).
The device's expanded monitoring capabilities have been designed to support clinical treatment decisions by providing critical care physicians with meaningful information to assess their patients' metabolic and haemodynamic status.
OptiScan Biomedical chairman and CEO Peter Rule said the company's goal in developing the new OptiScanner 6000 is to provide critical care physicians a single automated product that meets their most important real-time patient monitoring needs.
"We believe the product represents a true breakthrough as it offers highly accurate monitoring of multiple key analytes in the same, small sample of blood without requiring any calibration or a dedicated catheter.
"Critical care doctors are responsible for treating multiple patients with varying life-threatening conditions all at the same time. The more a platform like the OptiScanner can enhance their ability to make rapid yet informed treatment decisions based on real-time and trending data, the better equipped they will be to deliver optimal patient outcomes."
OptiScan Biomedical has presented the latest clinical data from its ongoing MANAGE II Study ('Manual vs Automated moNitoring Accuracy of GlucosE') in 93 patients.
The blinded study showed the difficulties related to management of blood glucose levels in the critical care setting.
Findings in the study showed that a significant portion of patients in the critical care unit experienced high blood sugar or hyperglycaemia.
Based on the positive results from the MANAGE I and MANAGE II studies, OptiScan will start a US-based pivotal trial with the OptiScanner 5000 for continuous blood glucose monitoring in the near future.